Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Next Previous
Search
Trial Profile

Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TRXE 002 (Primary) ; Antineoplastics
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Kazia Therapeutics

    • Most Recent Events

    • 10 Apr 2021 Results assessing safety, tolerability, pharmacokinetic and efficacy of TRX-E-002-1 (Cantrixil) in patients with treatment-refractory ovarian cancer, presented at the 112th Annual Meeting of the American Association for Cancer Research.
    • 01 Mar 2021 According to a Kazia Therapeutics media release, this study has met its primary endpoints.
    • 09 Dec 2020 According to a Kazia Therapeutics media release, the company expects the full data to be presented at a suitable academic conference and published in a peer-reviewed journal in 1H CY2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top